Drugs / 11C-MC1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03912428 | Jun 2019 → Jun 2024 | idiopathic inflammatory myopathy, rheumatoid arthritis | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05062083 | Jun 2022 → Sep 2023 | multiple sclerosis | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]MC1 | “The novel PET tracer [11C]MC1 was used to examine COX-2 expression” PMID 32359360 ↗ May 2020 |
| Modality | Diagnostic / imaging agent | “The novel PET tracer [11C]MC1 was used” PMID 32359360 ↗ May 2020 |
| Route | Intravenous | “about 10 mCi of \[11C\]MC1 intravenously” NCT03912428 ↗ |